Affimed and Genentech (Roche) entered an August 2018 strategic collaboration to develop NK cell engager-based immunotherapeutics. Affimed received $96M upfront and near-term funding plus up to $5.0B in development, regulatory, and commercial milestones across multiple undisclosed solid and hematologic tumor targets. Affimed leads early research using its ROCK platform; Genentech leads clinical development and commercialization worldwide.
Key facts
AnnouncedAug 27, 2018
Deal value$5.1B
Deal typeCo-Development
Therapeutic areaMultiple solid and hematologic tumors
IndicationsMultiple solid and hematologic tumors
Key assetsROCK platform-derived NK cell engagers
MechanismTetravalent, multi-specific innate immune cell (NK and T cell) engagers